Repligen Total Liab from 2010 to 2025

RGEN Stock  USD 167.53  1.87  1.10%   
Repligen Total Liabilities yearly trend continues to be very stable with very little volatility. Total Liabilities is likely to grow to about 909.7 M this year. Total Liabilities is the total amount of all liabilities that Repligen has, including both short-term and long-term liabilities. View All Fundamentals
 
Total Liabilities  
First Reported
1986-03-31
Previous Quarter
875.6 M
Current Value
814 M
Quarterly Volatility
205.9 M
 
Black Monday
 
Oil Shock
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Repligen financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Repligen's main balance sheet or income statement drivers, such as Depreciation And Amortization of 44.5 M, Interest Expense of 9.5 M or Total Revenue of 766.2 M, as well as many indicators such as Price To Sales Ratio of 10.05, Dividend Yield of 0.0 or PTB Ratio of 4.35. Repligen financial statements analysis is a perfect complement when working with Repligen Valuation or Volatility modules.
  
Check out the analysis of Repligen Correlation against competitors.
To learn how to invest in Repligen Stock, please use our How to Invest in Repligen guide.

Latest Repligen's Total Liab Growth Pattern

Below is the plot of the Total Liab of Repligen over the last few years. It is the total amount of all liabilities that a company has, including both short-term and long-term liabilities. Repligen's Total Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Repligen's overall financial position and show how it may be relating to other accounts over time.
Total Liab10 Years Trend
Slightly volatile
   Total Liab   
       Timeline  

Repligen Total Liab Regression Statistics

Arithmetic Mean317,519,351
Geometric Mean112,866,439
Coefficient Of Variation107.83
Mean Deviation292,862,068
Median155,018,000
Standard Deviation342,374,277
Sample Variance117220.1T
Range899.6M
R-Value0.94
Mean Square Error15365T
R-Squared0.88
Slope67,370,625
Total Sum of Squares1758302.2T

Repligen Total Liab History

2025909.7 M
2024866.3 M
2023853.2 M
2022614 M
2021608.3 M
2020373.7 M
2019340.3 M

About Repligen Financial Statements

Repligen investors utilize fundamental indicators, such as Total Liab, to predict how Repligen Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Total Liabilities866.3 M909.7 M

Pair Trading with Repligen

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Repligen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Repligen will appreciate offsetting losses from the drop in the long position's value.

Moving against Repligen Stock

  0.76DYN Dyne TherapeuticsPairCorr
  0.72KZR Kezar Life SciencesPairCorr
  0.67HCM HUTCHMED DRCPairCorr
  0.59EWTX Edgewise TherapeuticsPairCorr
  0.5JNJ Johnson JohnsonPairCorr
The ability to find closely correlated positions to Repligen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Repligen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Repligen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Repligen to buy it.
The correlation of Repligen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Repligen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Repligen moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Repligen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Repligen offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Repligen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Repligen Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Repligen Stock:
Check out the analysis of Repligen Correlation against competitors.
To learn how to invest in Repligen Stock, please use our How to Invest in Repligen guide.
You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Repligen. If investors know Repligen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Repligen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.83)
Earnings Share
(0.03)
Revenue Per Share
11.452
Quarterly Revenue Growth
0.097
Return On Assets
0.002
The market value of Repligen is measured differently than its book value, which is the value of Repligen that is recorded on the company's balance sheet. Investors also form their own opinion of Repligen's value that differs from its market value or its book value, called intrinsic value, which is Repligen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Repligen's market value can be influenced by many factors that don't directly affect Repligen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Repligen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Repligen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Repligen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.